UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer

Journal of clinical oncology, 2019-09, Vol.37 (27), p.2386-2397

2019

Volltextzugriff (PDF)

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

Journal of clinical oncology, 2019-09, Vol.37 (26), p.2317-2328

2019

Volltextzugriff (PDF)

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

The New England journal of medicine, 2011-12, Vol.365 (26), p.2473-2483

2011

Volltextzugriff (PDF)

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

Journal of clinical oncology, 2016-10, Vol.34 (28), p.3460-3473

2016

Volltextzugriff (PDF)

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

Gynecologic oncology, 2016-10, Vol.143 (1), p.3-15

2016

Volltextzugriff (PDF)

First-line Chemotherapy in Epithelial Ovarian Cancer

Clinical obstetrics and gynecology, 2012-03, Vol.55 (1), p.96-113

BOOKMAN, MICHAEL A

2012

Volltextzugriff (PDF)

Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome

Journal of rheumatology, 2018-10, Vol.45 (10), p.1406-1410

2018

Volltextzugriff (PDF)

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer

Journal of clinical oncology, 2015-09, Vol.33 (26), p.2841-2847

2015

Volltextzugriff (PDF)

Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer

Journal of clinical oncology, 2016-11, Vol.34 (32), p.3854-3863

2016

Volltextzugriff (PDF)

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

Journal of clinical oncology, 2009-03, Vol.27 (9), p.1419-1425

2009

Volltextzugriff (PDF)

Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis

Pain (Amsterdam), 2009-06, Vol.143 (3), p.238-245

2009

Volltextzugriff (PDF)

Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease

Arthritis research & therapy, 2019-11, Vol.21 (1), p.223-223, Article 223

2019

Volltextzugriff (PDF)

Optimal primary therapy of ovarian cancer

Annals of oncology, 2016-04, Vol.27 Suppl 1 (suppl_1), p.i58-i62

Bookman, M A

2016

Volltextzugriff (PDF)

Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study

Gynecologic oncology, 2015-10, Vol.139 (1), p.17-22

2015

Volltextzugriff (PDF)

Can we predict who lives long with ovarian cancer?

Cancer, 2019-12, Vol.125 (S24), p.4578-4581

Bookman, Michael A.

2019

Volltextzugriff (PDF)

Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial

Gynecologic oncology, 2022-02, Vol.164 (2), p.278-287

2022

Volltextzugriff (PDF)

Molecular wanderings through the DNA damage response and risk for ovarian cancer

JNCI : Journal of the National Cancer Institute, 2014-01, Vol.106 (1), p.djt350-djt350

Bookman, Michael A

2014

Volltextzugriff (PDF)

Content Validity of Sjögren’s Syndrome Symptom Diary and Functional Assessment of Chronic Illness Therapy-Fatigue in Patients with Sjögren’s

Rheumatology and therapy., 2022-12, Vol.9 (6), p.1559-1574

2022

Volltextzugriff (PDF)

Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2014-04, Vol.32 (12), p.1210-1217

2014

Volltextzugriff (PDF)

Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren’s

Rheumatology and therapy., 2022-12, Vol.9 (6), p.1499-1515

2022

Volltextzugriff (PDF)

Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group

Journal of clinical oncology, 2003-01, Vol.21 (2), p.283-290

2003

Volltextzugriff (PDF)

Second‐Line Treatment of Ovarian Cancer

The oncologist (Dayton, Ohio), 2000-02, Vol.5 (1), p.26-35

2000

Volltextzugriff (PDF)

The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer

Annals of oncology, 2010-10, Vol.21 (suppl-7), p.vii211-vii217

Bookman, M A

2010

Volltextzugriff (PDF)

Developmental Chemotherapy and Management of Recurrent Ovarian Cancer

Journal of clinical oncology, 2003-05, Vol.21 (10 suppl), p.149s-167

Bookman, Michael A

2003

Volltextzugriff (PDF)

Update of randomized trials in first-line treatment

Annals of oncology, 2011-12, Vol.22 Suppl 8, p.viii52-viii60

Bookman, Michael A

2011

Volltextzugriff (PDF)

1 – 25 von 1.323

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(895)
Mit Volltextzugriff
(912)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(499)
Life Sciences & Biomedicine
(428)
Humans
(367)
Female
(238)
Oncology
(139)
Middle Aged
(134)
Adult
(110)
Aged
(102)
Biological And Medical Sciences
(100)
Male
(96)
Medical Sciences
(79)
Ovarian Neoplasms - Drug Therapy
(74)
Social Sciences
(67)
Animals
(64)
Ovarian Cancer
(63)
Obstetrics & Gynecology
(62)
Ovarian Neoplasms - Pathology
(54)
Physical Sciences
(53)
General & Internal Medicine
(46)
Hematology, Oncology And Palliative Medicine
(45)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(7)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

First-line Chemotherapy in Epithelial Ovarian Cancer

Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer

Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis

Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease

Optimal primary therapy of ovarian cancer

Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study

Can we predict who lives long with ovarian cancer?

Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial

Molecular wanderings through the DNA damage response and risk for ovarian cancer

Content Validity of Sjögren’s Syndrome Symptom Diary and Functional Assessment of Chronic Illness Therapy-Fatigue in Patients with Sjögren’s

Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren’s

Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group

Second‐Line Treatment of Ovarian Cancer

The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer

Developmental Chemotherapy and Management of Recurrent Ovarian Cancer

Update of randomized trials in first-line treatment

Suchergebnisse filtern